TECNOTREE
4.8.2022 11:23:07 CEST | Business Wire | Press release
On Thursday, August 4, 2022, Tecnotree announced its financial results for the second quarter ended June 30, 2022. Tecnotree, the global Digital Business Support Systems (BSS) provider, reported a revenue of EUR 18.3 million in the second quarter, continuing its financial strength with considerable growth in MEA & APAC segments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220804005494/en/
Consolidated highlights of the results of Q2 and Half Year 2022:
- Net sales of EUR 18.3 million in the second quarter, showing 9% growth as compared to last year, and EUR 31.6 million for H1 with 13% growth from last year
- Operating result of EUR 5.1 million in the second quarter, and EUR 7.1 million for H1
- Earnings per share of EUR 0.01 in the second quarter, and EUR 0.02 for H1
- Order book at the end of the period EUR 72.8 million, with 32.4% growth as compared to last year
Tecnotree CEO Padma Ravichander said, “Our customers have responded to our digital stack offering, with a strong order book for which we need to invest to deliver expeditiously. Despite rising costs due to external factors leading to thinner first-half net result margins, we continue to deliver new deployments to Tier-1 clients, which requires a greater initial investment. This investment today will ensure long-term recurring revenue over the next 3-5 years with our new customers by bringing stability. Our Digital Stack 5.0 is richer and capable of serving multiple markets and customers simultaneously.”
Other achievements for the second quarter:
- Achieving the highest order book position of EUR 72.8 million - 32% higher than H1 in 2021, due to a surge in demand for Tecnotree products and solutions in the first half of 2022, with continued support from large tier 1 telecom groups such as MTN, STC, Zain, Ooredoo
- Tecnotree digital BSS suite 5 went live for enterprise and consumer businesses for MTN Uganda, driving process agility and customer delight
- Launch of digital transformation suite for MTN Ghana to meet enterprise market demand and deliver augmented customer experiences
- Tecnotree Awarded as 'Change-maker of the year' by the Helsinki Stock Exchange Foundation, for being instrumental in driving growth in emerging markets with its 5G-ready digital products and solutions
- Launch of 5G cloud-native Digital Provisioning Platform for Zain South Sudan, and another tier 1 operator in the Middle East. Tecnotree DSPS is a pre-integrated suite that enables a centralized system for all provisioning-related planning and task management
- Tecnotree wins ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ for enabling customers to transition to new technologies and digital ecosystems
- Launch of DOCS, a 5G Digital Convergent Charging Platform which supports existing and futuristic monetization requirements of CSPs across the verticals and industries
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) provider, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com or social media channels – LinkedIn I Facebook I Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005494/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom